{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T18:19:43Z","timestamp":1791397183165,"version":"4.3.3"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T00:00:00Z","timestamp":1774828800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T00:00:00Z","timestamp":1774828800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1007\/s12325-026-03538-y","type":"journal-article","created":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T08:01:11Z","timestamp":1774857671000},"page":"2550-2567","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["A Retrospective Observational Study of Safety and Effectiveness of Abemaciclib in Chinese Patients with Breast Cancer"],"prefix":"10.1007","volume":"43","author":[{"given":"Fangyuan","family":"Zhao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaxin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanfang","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinyi","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiping","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qimin","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,30]]},"reference":[{"issue":"3","key":"3538_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"issue":"20","key":"3538_CR2","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1097\/CM9.0000000000003278","volume":"137","author":"K Sun","year":"2024","unstructured":"Sun K, Zhang B, Lei S, et al. Incidence, mortality, and disability-adjusted life years of female breast cancer in China, 2022. Chin Med J (Engl). 2024;137(20):2429\u201336.","journal-title":"Chin Med J (Engl)"},{"key":"3538_CR3","unstructured":"National Cancer Institute Surveillance Epidemiology and End Results Program (SEER). SEER cancer stat facts: female breast cancer subtypes. 2018\u20132022. https:\/\/seer.cancer.gov\/statfacts\/html\/breast-subtypes.html. Accessed Sept 2025."},{"issue":"9","key":"3538_CR4","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1038\/s41417-024-00747-x","volume":"31","author":"X Wang","year":"2024","unstructured":"Wang X, Zhao S, Xin Q, Zhang Y, Wang K, Li M. Recent progress of CDK4\/6 inhibitors\u2019 current practice in breast cancer. Cancer Gene Ther. 2024;31(9):1283\u201391.","journal-title":"Cancer Gene Ther"},{"issue":"2","key":"3538_CR5","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s40487-018-0062-x","volume":"6","author":"SJ Johnston","year":"2018","unstructured":"Johnston SJ, Cheung KL. Endocrine therapy for breast cancer: a model of hormonal manipulation. Oncol Ther. 2018;6(2):141\u201356.","journal-title":"Oncol Ther"},{"issue":"4","key":"3538_CR6","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1159\/000508675","volume":"15","author":"AD Hartkopf","year":"2020","unstructured":"Hartkopf AD, Grischke EM, Brucker SY. Endocrine-resistant breast cancer: mechanisms and treatment. Breast Care (Basel). 2020;15(4):347\u201354.","journal-title":"Breast Care (Basel)"},{"issue":"5","key":"3538_CR7","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s10637-014-0120-7","volume":"32","author":"LM Gelbert","year":"2014","unstructured":"Gelbert LM, Cai S, Lin X, et al. Preclinical characterization of the CDK4\/6 inhibitor LY2835219: in-vivo cell cycle-dependent\/independent anti-tumor activities alone\/in combination with gemcitabine. Invest New Drugs. 2014;32(5):825\u201337.","journal-title":"Invest New Drugs"},{"key":"3538_CR8","unstructured":"US Food and Drug Administration (FDA). VERZENIOS\u00ae (abemaciclib) tablets, for oral use. Indianapolis, IN, USA: Eli Lilly and Company. 2021. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/208716s006s007s008lbl.pdf. Accessed Aug 2025."},{"issue":"25","key":"3538_CR9","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.1200\/JCO.2017.73.7585","volume":"35","author":"GW Sledge Jr","year":"2017","unstructured":"Sledge GW Jr, Toi M, Neven P, et al. MONARCH\u00a02: abemaciclib in combination with fulvestrant in women with HR+\/HER2- advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol. 2017;35(25):2875\u201384.","journal-title":"J Clin Oncol"},{"key":"3538_CR10","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41523-018-0097-z","volume":"5","author":"S Johnston","year":"2019","unstructured":"Johnston S, Martin M, Di Leo A, et al. MONARCH\u00a03 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer. NPJ Breast Cancer. 2019;5:5.","journal-title":"NPJ Breast Cancer"},{"key":"3538_CR11","doi-asserted-by":"publisher","first-page":"175883592096392","DOI":"10.1177\/1758835920963925","volume":"12","author":"QY Zhang","year":"2020","unstructured":"Zhang QY, Sun T, Yin YM, et al. MONARCH\u00a0plus: abemaciclib plus endocrine therapy in women with HR+\/HER2- advanced breast cancer: the multinational randomized phase\u00a0III study. Ther Adv Med Oncol. 2020;12:1758835920963925.","journal-title":"Ther Adv Med Oncol"},{"issue":"12","key":"3538_CR12","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1097\/CM9.0000000000003151","volume":"138","author":"X Hu","year":"2025","unstructured":"Hu X, Zhang Q, Sun T, et al. Abemaciclib plus non-steroidal aromatase inhibitor or fulvestrant in women with HR+\/HER2- advanced breast cancer: final results of the randomized phase\u00a0III MONARCH\u00a0plus trial. Chin Med J (Engl). 2025;138(12):1477\u201386.","journal-title":"Chin Med J (Engl)"},{"issue":"34","key":"3538_CR13","doi-asserted-by":"publisher","first-page":"3987","DOI":"10.1200\/JCO.20.02514","volume":"38","author":"SRD Johnston","year":"2020","unstructured":"Johnston SRD, Harbeck N, Hegg R, et al. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer (monarchE). J Clin Oncol. 2020;38(34):3987\u201398.","journal-title":"J Clin Oncol"},{"issue":"2","key":"3538_CR14","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.annonc.2025.10.005","volume":"37","author":"S Johnston","year":"2026","unstructured":"Johnston S, Martin M, O\u2019Shaughnessy J, et al. Overall survival with abemaciclib in early breast cancer. Ann Oncol. 2026;37(2):155\u201365.","journal-title":"Ann Oncol"},{"key":"3538_CR15","doi-asserted-by":"publisher","DOI":"10.1177\/17588359241286775","volume":"16","author":"Q Zhang","year":"2024","unstructured":"Zhang Q, Shen K, Song CG, et al. Abemaciclib combined with endocrine therapy as adjuvant treatment for hormone-receptor-positive, HER2-, high-risk early breast cancer: 5-year Chinese population analysis of the phase\u00a0III randomized monarchE study. Ther Adv Med Oncol. 2024;16:17588359241286775.","journal-title":"Ther Adv Med Oncol"},{"key":"3538_CR16","unstructured":"Chinese National Medical Products Administration (NMPA). Abemaciclib prescribing information 2025. https:\/\/www.lillymedical.cn\/file\/raw\/f4e09dab-5cac-445c-91f1-1222ec5bbb93\/%25E9%2598%25BF%25E8%25B4%259D%25E8%25A5%25BF%25E5%2588%25A9%25E7%2589%2587%25E8%25AF%25B4%25E6%2598%258E%25E4%25B9%25A6.pdf. Accessed Jan 2026."},{"issue":"12","key":"3538_CR17","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.1016\/j.annonc.2021.09.019","volume":"32","author":"A Gennari","year":"2021","unstructured":"Gennari A, Andr\u00e9 F, Barrios CH, et al. ESMO clinical practice guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol. 2021;32(12):1475\u201395.","journal-title":"Ann Oncol"},{"issue":"2","key":"3538_CR18","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.annonc.2023.11.016","volume":"35","author":"S Loibl","year":"2024","unstructured":"Loibl S, Andr\u00e9 F, Bachelot T, et al. Early breast cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2024;35(2):159\u201382.","journal-title":"Ann Oncol"},{"issue":"10","key":"3538_CR19","first-page":"838","volume":"21","author":"J Li","year":"2024","unstructured":"Li J, Jiang Z. Chinese Society of Clinical Oncology Breast Cancer (CSCO BC) Guidelines in 2024: international contributions from China. Cancer Biol Med. 2024;21(10):838\u201343.","journal-title":"Cancer Biol Med"},{"key":"3538_CR20","doi-asserted-by":"publisher","first-page":"4","DOI":"10.21037\/tbcr-21-36","volume":"3","author":"L Yang","year":"2022","unstructured":"Yang L, Chen Y, Wang N, Han W. A narrative review of the clinical development of CDK4\/6 inhibitor abemaciclib in breast cancer. Transl Breast Cancer Res. 2022;3:4.","journal-title":"Transl Breast Cancer Res"},{"issue":"20","key":"3538_CR21","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","volume":"310","author":"World Medical Association","year":"2013","unstructured":"World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191\u20134.","journal-title":"JAMA"},{"issue":"6","key":"3538_CR22","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.annonc.2022.03.006","volume":"33","author":"HS Rugo","year":"2022","unstructured":"Rugo HS, O\u2019Shaughnessy J, Boyle F, et al. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE study. Ann Oncol. 2022;33(6):616\u201327.","journal-title":"Ann Oncol"},{"issue":"1","key":"3538_CR23","doi-asserted-by":"publisher","first-page":"e53","DOI":"10.1002\/onco.13531","volume":"26","author":"HS Rugo","year":"2021","unstructured":"Rugo HS, Huober J, Garc\u00eda-S\u00e1enz JA, et al. Management of abemaciclib-associated adverse events in patients with hormone receptor-positive, human epidermal growth factor receptor\u00a02-negative advanced breast cancer: safety analysis of MONARCH\u00a02 and MONARCH\u00a03. Oncologist. 2021;26(1):e53\u201365.","journal-title":"Oncologist"},{"issue":"9","key":"3538_CR24","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.3390\/biom13091422","volume":"13","author":"IM Stanciu","year":"2023","unstructured":"Stanciu IM, Parosanu AI, Nitipir C. An overview of the safety profile and clinical impact of CDK4\/6 inhibitors in breast cancer-a systematic review of randomized phase\u00a0II and III clinical trials. Biomolecules. 2023;13(9):1422.","journal-title":"Biomolecules"},{"issue":"1","key":"3538_CR25","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s10549-020-06001-w","volume":"186","author":"E Raschi","year":"2021","unstructured":"Raschi E, Fusaroli M, Ardizzoni A, Poluzzi E, De Ponti F. Cyclin-dependent kinase 4\/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system: a pharmacovigilance assessment. Breast Cancer Res Treat. 2021;186(1):219\u201327.","journal-title":"Breast Cancer Res Treat"},{"key":"3538_CR26","doi-asserted-by":"crossref","unstructured":"Ouyang Q, Yuan P, Liu J, et al. A prospective post-marketing observational study of abemaciclib in patients with HR+, HER2\u2212 breast cancer in China. Oncologist. 2026:oyag013. Epub ahead of print.","DOI":"10.1093\/oncolo\/oyag013"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03538-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03538-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03538-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T04:51:04Z","timestamp":1780116664000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03538-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,30]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["3538"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03538-y","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,30]]},"assertion":[{"value":"22 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Liu Yang, Qinyi Zhu, and Xiao Ma are employees of Eli Lilly and Company. Fangyuan Zhao, Yaxin Liu, Hanfang Jiang, Huiping Li, and Qimin Zhan have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study adhered to international ethics guidelines, including the Declaration of Helsinki. The study protocol and waiver of informed consent was approved by the independent ethics committee of Beijing Cancer Hospital (Approval No. 2023YW172; 15 September 2023).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}